Stocks · News reference

Lexicon Pharmaceuticals shares are trading higher after Cantor Fitzgerald initiated coverage on the stock with an Overweight rating and announced an $8 price target.

Sep 28, 2026, 2:13 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

The Motley FoolSep 28, 2026, 9:05 PMEric Volkman
Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today
Lexicon Pharmaceuticals stock surged nearly 6% after analyst Steve Seedhouse from Cantor Fitzgerald initiated coverage with an 'overweight' rating and $8 price target (over 4x the current $1.90 price). Seedhouse highlighted the company's progress on sotagliflozin, an FDA-approved heart failure drug being developed for hypertrophic cardiomyopathy, which works through a different mechanism than competing treatments.
LXRX
BenzingaSep 28, 2026, 12:34 PMAvi Kapoor
This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Analysts initiate coverage: Buy on IonQ ($60), Jack Henry ($193) and 10X Genomics ($110); Overweight Lexicon ($8); In-Line Fortive ($60).
FTV IONQ JKHY LXRX TXG
BenzingaSep 28, 2026, 10:39 AMBenzinga Newsdesk
Cantor Fitzgerald Initiates Coverage On Lexicon Pharmaceuticals with Overweight Rating, Announces Price Target of $8
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Overweight rating and announces Price Target of $8.
LXRX